Related Experiment Video
Updated: Jul 4, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration
Mohamed A Ghoneim1, Mahmoud M Gabr2, Sawsan M El-Halawani2
1The Urology and Nephrology Center, Mansoura, Egypt. ghoneimma@yahoo.com.
Abstract:
Over the past decade, there had been progress in the development of cell therapy for insulin-dependent diabetes. Nevertheless, important hurdles that need to be overcome still remain. Protocols for the differentiation of pluripotent stem cells into pancreatic progenitors or fully differentiated β-cells have been developed. The resulting insulin-producing cells can control chemically induced diabetes in rodents and were the subject of several clinical trials. However, these cells are immunogenic and possibly teratogenic for their transplantation, and an immunoisolation device and/or immunosuppression is needed. A growing number of studies have utilized genetic manipulations to produce immune evasive cells. Evidence must be provided that in addition to the expected benefit, gene manipulations should not lead to any unforeseen complications. Mesenchymal stem/stromal cells (MSCs) can provide a viable alternative. MSCs are widely available from many tissues. They can form insulin-producing cells by directed differentiation. Experimentally, evidence has shown that the transplantation of allogenic insulin-producing cells derived from MSCs is associated with a muted allogeneic response that does not interfere with their functionality. This can be explained by the immunomodulatory functions of the MSC subpopulation that did not differentiate into insulin-producing cells. Recently, exosomes derived from naive MSCs have been used in the experimental domain to treat diabetes in rodents with varying degrees of success. Several mechanisms for their beneficial functions were proposed including a reduction in insulin resistance, the promotion of autophagy, and an increase in the T regulatory population. However, euglycemia was not achieved in any of these experiments. We suggest that exosomes derived from β-cells or insulin-producing cells (educated) can provide a better therapeutic effect than those derived from undifferentiated cells.
Insights
Cell therapy for diabetes shows promise, but faces challenges like immune rejection. Mesenchymal stem cells and their exosomes offer potential alternatives, with educated exosomes showing superior therapeutic prospects.
Area of Science:
- Regenerative Medicine
- Endocrinology
- Immunology
Background:
- Cell therapy for insulin-dependent diabetes has advanced, yet faces significant hurdles.
- Current approaches using differentiated stem cells are immunogenic and potentially teratogenic, necessitating immunosuppression or immunoisolation.
- Genetic modifications aim for immune evasion but require safety validation.
Purpose of the Study:
- To explore mesenchymal stem/stromal cells (MSCs) as an alternative for diabetes cell therapy.
- To investigate the therapeutic potential of exosomes derived from MSCs and insulin-producing cells for diabetes treatment.
Main Methods:
- Development of protocols for differentiating pluripotent stem cells into insulin-producing cells.
- Utilizing genetic modifications to create immune-evasive cells.
- Directed differentiation of MSCs into insulin-producing cells.
- Experimental transplantation of allogeneic MSC-derived insulin-producing cells.
- Analysis of exosomes derived from naive MSCs for therapeutic effects in rodent models.
Main Results:
- Differentiated stem cells showed efficacy in rodent models but pose immunogenicity and teratogenicity risks.
- Transplantation of allogeneic MSC-derived insulin-producing cells exhibited a muted allogeneic response due to MSC immunomodulatory properties.
- Exosomes from naive MSCs demonstrated some benefits in rodents, including reduced insulin resistance and increased regulatory T cells, but did not achieve euglycemia.
Conclusions:
- MSCs present a viable alternative for cell therapy in diabetes due to their differentiation capacity and immunomodulatory effects.
- Exosomes derived from MSCs show therapeutic promise, but their efficacy is limited.
- Educated exosomes, derived from β-cells or insulin-producing cells, are hypothesized to offer superior therapeutic benefits compared to exosomes from undifferentiated cells.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Induced Pluripotent Stem Cells
iPS Cell Differentiation
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Stem Cell Culture

